TNF inhibitors like adalimumab and etanercept help control autoimmune diseases but raise concerns about cancer risk. Real-world data shows no overall increase in cancer, but skin cancer risk is slightly higher-especially with adalimumab. Regular skin checks and steroid reduction are key.